3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Seizures
1
Pinealoma
1
Pain, Intractable
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Meningioma
1
Medulloblastoma
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Bone Neoplasms
1
Astrocytoma
1
Interventions
Ibandronic Acid
8
Gemcitabine
8
Doxorubicin
6
Cyclophosphamide
6
Zoledronic Acid
5
Radiation
4
Nivolumab
4
Irinotecan
4
pembrolizumab
3
Vincristine
3
Temozolomide
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Docetaxel
3
Denosumab
3
Cisplatin
3
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
3
regorafenib
2
pegfilgrastim
2
Tranexamic Acid
2
Trabectedin
2
Surveys and Questionnaires
2
Sunitinib
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiosurgery
2
Quality of Life
2
Proton Therapy
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bone Neoplasms
×
Pregabalin
×
Sarcoma
×
Clear all
NCT00381095
2021-01-20
COPE
Pfizer
Phase 4
Terminated
152 enrolled
14 charts